The p38 MAPK-regulated PKD1/CREB/Bcl-2 pathway contributes to selenite-induced colorectal cancer cell apoptosis in vitro and in vivo  by Hui, Kaiyan et al.
The p38 MAPK-regulated PKD1/CREB/Bcl-2 pathway contributes to
selenite-induced colorectal cancer cell apoptosis in vitro and in vivo
Kaiyan Hui, Yang Yang, Kejian Shi, Hui Luo, Jing Duan, Jiajia An, Pa Wu, Yali Ci, Lei Shi,
Caimin Xu *
National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences and School of Basic Medicine, Peking Union Medical College and
Chinese Academy of Medical Sciences, NO. 5 Dong Dan San Tiao, Beijing 100005, China
A R T I C L E I N F O
Article history:
Received 4 May 2014
Received in revised form 5 August 2014
Accepted 6 August 2014
Keywords:
Selenite
Apoptosis
p38 MAPK
PKD1
CREB
A B S T R A C T
Supranutritional selenite has anti-cancer therapeutic effects in vivo; however, the detailed mechanisms
underlying these effects are not clearly understood. Further studies would broaden our understanding
of the anti-cancer effects of this compound and provide a theoretical basis for its clinical application. In
this study, we primarily found that selenite exposure inhibited phosphorylation of cyclic adenosine mono-
phosphate (cAMP)-response element binding protein (CREB), leading to suppression of Bcl-2 in HCT116
and SW480 colorectal cancer (CRC) cells. Moreover, the selenite-induced inhibitory effect on PKD1 ac-
tivation was involved in suppression of the CREB signalling pathway. Additionally, we discovered that
selenite treatment can upregulate p38 MAPK phosphorylation, which results in inhibition of the PKD1/
CREB/Bcl-2 survival pathway and triggers apoptosis. Finally, we established a colorectal cancer xenograft
model and found that selenite treatment markedly inhibits tumour growth through the MAPK/PKD1/
CREB/Bcl-2 pathway in vivo. Our results demonstrated that a supranutritional dose of selenite induced
CRC cell apoptosis through inhibition of the PKD1/CREB/Bcl-2 axis both in vitro and in vivo.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Introduction
The essential trace element selenium (Se) is involved in several
physiological processes of the body and has been applied to cancer
prevention and treatment [1,2]. Selenite compounds induce apop-
tosis, an important cellular event that accounts for the anti-
cancer effects of selenite [3,4]. Evidence from several cancer cell lines
has demonstrated that sodium selenite treatment leads to cell
apoptosis [5–7].
The cyclic adenosinemonophosphate (cAMP) response element-
binding protein (CREB) is necessary for the proliferation, growth,
survival, and differentiation of many cell types [8]. Recent research
has demonstrated that CREB regulates the expression of a reper-
toire of genes associated with cell survival, such as Bcl-2, Bcl-xL,
c-fos and tumour necrosis factor-α (TNF-α) [9–12]. Furthermore, the
selenite-induced inhibition of CREB-Ser133 phosphorylation results
in the suppression of anti-apoptotic genes, which induces cell death
[13–15]. Numerous reports have proposed that CREB is regulated
by multiple protein kinases, such as extracellular signal-regulated
kinase (ERK), protein kinase D1 (PKD1) and mitogen- and stress-
activated protein kinase (MSK) [16–19]. Clarifying the regulatory
network of CREBwould greatly contribute to the discovery of novel
molecular mechanisms controlling apoptosis and would provide a
broader signiﬁcance for future clinical applications of selenium.
In the present study, we discovered that selenite down-regulates
the PKD1/CREB/Bcl-2 axis and induces apoptosis in CRC cells. In vivo
experiments conﬁrmed these therapeutic effects of selenite and the
alterations of these proteins that were observed in vitro. Together,
these experiments indicate that selenite has potential for future clin-
ical applications.
Materials and methods
Cell lines and culture
HCT116 and SW480 colorectal cancer cells weremaintained in DMEM (Invitrogen,
Paisley, Scotland) supplemented with 10% foetal bovine serum (FBS; Hyclone, Logan,
UT, USA) and antibiotics (100 units/ml penicillin and 100 μg/ml streptomycin) in a
humidiﬁed 5% CO2 atmosphere at 37 °C. All of the cell cultures were discarded after
2 months, and new cell lines were propagated from frozen stocks.
Reagents and antibodies
Sodium selenite was purchased from Sigma-Aldrich (St. Louis, MO, USA) and a
10 μM working solution was used in this study. SB203580, phorbol-12-myristate-
13-acetate (PMA), and CID755673 were purchased from Merck Calbiochem
(San Diego, CA, USA). The CBP–CREB interaction inhibitor was purchased fromMED
Chemicals (San Diego, CA, USA). The pCF-CREB, p-CDNA3-FLAG-p38, and p-CDNA3-
FLAG-p38DNvectorswereobtained fromAddgene (www.addgene.org), and thepEGFP-
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HA-PKD1 WT and pEGFP-HA-PKD1 KD vectors were a kind gift from Dr. Angelika
Hausser. Antibodies recognising cleaved PARP, cleaved caspase-9, p-PKD1 (Ser744),
p-PKD1 (Ser916), PKD1, p-p38 MAPK, HA-tag and FLAG-tag were purchased from
Cell Signaling Technology (Beverly,MA, USA). Antibodies recognising p-CREB (Sre133)
and CREB were obtained from ExCell Biology (Shanghai, China). Antibodies against
B23, Bcl-2 and p38 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). For immunohistochemical staining, an anti-p-PKD1 (Ser916) antibodywas pur-
chased from Abcam (Cambridge, UK), and the antibody against PKD1 was obtained
from Santa Cruz Biotechnology. The antibody against p-PKD1 (Ser916) used for im-
munoﬂuorescence was purchased from GeneTex (GeneTex, CA, USA).
Fig. 1. Sodium selenite inhibits CREB signalling in CRC cells. (A) Sodium selenite inhibited CREB phosphorylation and induced apoptosis in CRC cells. HCT116 and SW480
cells were treated with selenite (10 μM) for the time points indicated. CREB, p-CREB and apoptosis markers were detected by western blot and quantiﬁed by pixel densi-
tometry. (B) Selenite treatment speciﬁcally decreased p-CREB in the nucleus of CRC cells. The nuclear and cytoplasmic fractions were prepared from selenite-treated and
control cells, and p-CREB was detected by western blot and quantiﬁed by pixel densitometry. β-actin and B23 were used as loading controls for the cytoplasmic and nuclear
fractions, respectively.
Fig. 2. Selenite suppresses CREB phosphorylation and subsequently reduces Bcl-2 expression. (A) Selenite promotes p-CREB binding to the Bcl-2 promoter. CRC cells were
treated with or without selenite (10 μM) for 24 h, and CREB-DNA binding was then analysed with a ChIP assay. The transcriptional level of β-actin was detected as input.
(B) Selenite decreased Bcl-2 expression in both HCT116 and SW480 CRC cells. The western blot assay showed that selenite decreased Bcl-2 expression in both HCT116 and
SW480 CRC cells. (C) CREB knockdown decreased the Bcl-2 levels. The cells were transfected with a siRNA targeting CREB and then treated with 10 μM selenite for 24 h.
Next, the Bcl-2, CREB and apoptosis markers levels were detected by western blot and quantiﬁed by pixel densitometry. (D) CREB knockdown enhanced the degree of apop-
tosis induced by selenite. The cells were treated as described in (C), and the number of apoptotic cells was then determined by ﬂow cytometry. The data are represented as
the means ± SD (n = 3). *P < 0.05. (E) The overexpression of constitutively active CREB reversed the selenite-induced apoptosis and decrease in Bcl-2 expression. After trans-
fection with constitutive actively CREB plasmids, the cells were cultured for 24 h and then treated with 10 μM selenite for 24 h. The Bcl-2, CREB and apoptotic markers
levels were detected by western blot and quantiﬁed by pixel densitometry. (F) The overexpression of constitutively active CREB reduced the selenite-induced apoptosis.
The cells were treated as described in (E), and the apoptotic cells were then detected by ﬂow cytometry. (G) Inhibition of CREB transcriptional activity further decreased
the levels of Bcl-2 and enhanced the extent of selenite-induced apoptosis. The cells were pretreated with 3 mM CBP–CREB interaction inhibitor for 2 h and then treated
with 10 μM selenite for 24 h. The Bcl-2, CREB and apoptosis marker levels were detected by western blot and quantiﬁed by pixel densitometry. (H) CREB inhibition further
enhanced the degree of apoptosis induced by selenite. The cells were treated as described in (G), and the apoptotic cells were then detected by ﬂow cytometry. The data
are represented as the means ± SD (n = 3). *P < 0.05.
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Western blot assay
The total proteins were extracted and separated as described previously and then
quantiﬁed by pixel densitometry using the ImageJ® software and expressed as
means ± SD (n = 3) [7]. Speciﬁcally, the cytoplasmic and nuclear fractions were pre-
pared according to the manufacturer’s instructions for the NE-PER Nuclear and
Cytoplasmic Extraction Reagents (Pierce, Rockford, IL, USA).
Transient transfection analysis
Approximately 4 × 105 cells were plated into six-well plate 1 day before the trans-
fection experiments to allow for cell attachment and growth. The cells were transfected
with the indicated plasmids using Lipofectamine 2000 reagent (Invitrogen, Carls-
bad, CA, USA) according to the manufacturer’s protocol. Brieﬂy, approximately 4 μg
of each plasmid was transfected into cells together with 5 μl of Lipofectamine 2000
reagent per well, and the cells were treated as indicated 24 h later.
Small interfering RNAs
The p38 MAPK siRNA (5′-GGAAUUCAAUGAUGUGUA-3′) was chemically
synthesised by GenePharm (Shanghai, China). The CREB siRNA (h) and PKD1 siRNA
(h) were purchased from Santa Cruz Biotechnology. The cells were cultured in six-
well plates before transfectionwith 100 pM siRNA using Lipofectamine 2000 according
to the guidelines described earlier. The cells were then subjected to further treat-
ment as indicated.
Co-immunoprecipitation
The cells were harvested and washed twice with ice-cold PBS and then lysed
in RIPA buffer for 30 min. Then 200-μg aliquots of the lysates were incubated with
the appropriate antibodies to immunoprecipitate the proteins of interest. The pro-
teins bound to the antibodies were then captured with 25 μl of protein A + G agarose
beads (Santa Cruz Biotechnology). After washing and elution, the immunoprecipi-
tates were resuspended in western blot sample buffer and boiled for 10 min. The
samples were then used for the western blot assays.
Immunoﬂuorescence
The cells were grown on coverslips for 24 h before treatment with 10 μM sel-
enite for 24 h. The cells were then ﬁxed in Immunol staining ﬁx solution (Beyotime,
Haimen, Jiangsu, China) for 10 min. After washing with PBS three times for 5 min
each, samples were blocked with Immunol staining blocking buffer (Beyotime) for
30 min at room temperature. Subsequently, the slides were incubated with the in-
dicated primary antibodies overnight at 4 °C. The cells were then incubated with
the appropriate secondary antibodies for 1 h at room temperature, followed by coun-
terstaining with DAPI. Images were acquired on an Olympus laser scanning confocal
FV1000 microscope (Olympus, Tokyo, Japan) and analysed using the Olympus Fluo
View software.
Apoptosis assay
The percentage of cells undergoing apoptosis was determined with an Annexin
V/PI double staining kit fromMerck Calbiochem according to the manufacturer’s in-
structions. The ﬂuorescence was detected with an Accuri C6 ﬂow cytometer (Accuri
Cytometers Inc., Ann Arbor, MI, USA). We calculated the apoptotic ratio by calcu-
lating the sum of the Annexin V+/PI− cells ratios and the Annexin V+/PI+ cells’ ratio.
All of the experiments were repeated thrice independently, and the data are rep-
resented as the means ± SD (n = 3). *P < 0.05.
ChIP assay
ChIP assays were performed using the Simple ChIP Enzymatic Chromatin IP Kit
purchased from Cell Signaling Technology. Chromatin extracts were immunopre-
cipitated using an antibody against p-CREB and analysed by subsequent PCR
with the following primers for β-actin and Bcl-2: β-actin forward, 5′-
CATGTTTGAGACCTTCAACACCCC-3′; β-actin reverse, 5′-GCCATCTCTTGCTCGAAGTCTAG-
3′; Bcl-2 forward, 5′-GCCCGACTTTGCAGAGATGTCCAG-3′; and Bcl-2 reverse, 5′-
GCCATGCCGGTTCAGGTACTCAG-3′.
Xenograft tumour model
BALB/c (nu/nu) nude mice were individually caged in standard laboratory con-
ditions and provided food and water ad libitum. Four-week-old female nude mice
were injected with HCT116 and SW480 cells. After tumours were detectable, the
mice were randomly divided into three groups (each group contained seven mice)
and treated with PBS or selenite every 2 days (2 mg/kg/day or 1 mg/kg/day). After
3 weeks of this treatment, the mice were killed for analysis. The animals were main-
tained and tested according to the Guidelines for the Declaration of Helsinki and/
or the Guide for the Care and Use of Laboratory Animals as adopted and promulgated
by the United States National Institutes of Health.
Immunohistochemical staining
Portions of the tissue samples of the xenograft tumour model were homogenised
and subjected to western blotting, and the remaining tissues were embedded for
immunohistochemical analysis as described previously [20].
Statistical analysis
Each experiment was repeated at least thrice. For all of the quantitative anal-
yses represented in the histograms, the values are expressed as the mean values ± SD.
Two-tailed Student’s t-tests were performed to compare two groups. P < 0.05 was
considered signiﬁcant.
Results
Selenite suppresses CREB phosphorylation and induces apoptosis in
CRC cells
CREB is essential for the proliferation, growth and survival of
various types of cancer cells. Phosphorylation of the Ser133 residue
in CREB is necessary for the transcriptional activation of anti-
apoptotic gene expression [10,15,21]. To elucidate the detailed
molecular mechanism of selenite-induced apoptosis in CRC cells,
we ﬁrst investigated the effect of selenite on CREB in CRC cells. Our
previous work indicated that a supranutritional dose of sodium sel-
enite (10 μM) induces apoptosis in CRC cells. As shown in Fig. 1A,
in the presence of 10 μM selenite, CREB phosphorylation at Ser133
decreased over time in both CRC cell lines tested, whereas PARP and
caspase-9 cleavage increased. It is widely recognised that CREB is
located in the nucleus as a transcription factor [14,16,22]. We ex-
tracted the nuclear fraction of selenite-treated CRC cells and
discovered that 10 μM selenite treatment decreased CREB-Ser133
phosphorylation in the nucleus at 24 h without altering the total
CREB levels (Fig. 1B). Taken together, these results demonstrate that
selenite inhibits CREB phosphorylation in the nucleus.
Selenite suppresses CREB phosphorylation and subsequently reduces
Bcl-2 expression
In the nucleus, activated CREB can bind to promoters contain-
ing a consensus sequence to enhance the transcription of various
survival proteins including Bcl-2 [8,16,18,22]. Bcl-2 family pro-
teins are essential regulators of selenite-induced apoptosis [23–25].
Fig. 3. Selenite-treatment suppressed CREB/Bcl-2 signalling by inhibiting PKD1 activity. (A, C and E) PKD1 inhibition decreased the levels of CREB phosphorylation and Bcl-2
expression and increased selenite-induced apoptosis. The cells were transfected with siRNA targeting PKD1 or a PKD1-overexpressing KD plasmid or pre-treated with 1 μM
CID 755673 for 2 h. The cells were then treated with selenite (10 μM) for 24 h, and the PKD1, CREB, Bcl-2 and apoptosis marker levels were detected by western blot and
quantiﬁed by pixel densitometry. (B, D and F) PKD1 inhibition further enhanced the degree of apoptosis induced by selenite. The cells were treated as described in (A, C
and E), and the apoptotic cells were measured by ﬂow cytometry. The data are represented as the means ± SD (n = 3). *P < 0.05. (C and G) PKD1 activation increased CREB
phosphorylation and Bcl-2 expression. The cells were transfected with PKD1 WT or pretreated with 100 nM PMA for 2 h. After the cells were treated with 10 μM selenite
for 24 h, the PKD1, CREB, Bcl-2 and apoptosis marker levels were detected by western blot and quantiﬁed by pixel densitometry. (D and F) PKD1 activation reversed the
selenite-induced apoptosis. The cells were treated as described in (C and G), and the apoptotic cells were measured by ﬂow cytometry. The data are represented as
the means ± SD (n = 3). *P < 0.05. (I) PKD1 interacts with CREB. The cells were exposed to 10 μM selenite for 24 h, and co-immunoprecipitation was used to detect the in-
teractions between PKD1 and CREB. (J) The co-localisation of PKD1 and CREB was reduced after selenite exposure. The cells were treated with 10 μM selenite for 24 h, and
PKD1 and CREB were indirectly labelled with primary antibodies. The images were generated with a confocal microscope. Bar: 10 μm.
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Thus, we performed chromatin immunoprecipitation (ChIP) ex-
periments to examine whether selenite treatment inﬂuences p-CREB
binding to the Bcl-2 promoter and subsequently regulates Bcl-2 tran-
scription. Indeed, as shown in Fig. 2A, selenite treatment in HCT116
and SW480 CRC cells reduced CREB binding to the Bcl-2 promot-
er, whichmay result from the decreased CREB phosphorylation levels
observed previously. Accordingly, our western blot results
indicated that selenite treatment suppressed Bcl-2 expression
(Fig. 2B).
Next, following pre-treatment with a siRNA targeting CREB, the
cells were exposed to selenite for 24 h. The western blot results
indicated that the knockdown of CREB further reduced Bcl-2 ex-
pression while simultaneously increasing PARP and caspase-9
cleavage (Fig. 2C). An analysis of the apoptotic rate of these cells
demonstrated that CREB suppression enhanced apoptosis in
selenite-treated CRC cells (Fig. 2D, Supplementary Fig. 2D). On the
contrary, when we over-expressed a constitutively active CREB, we
observed that the selenite-induced Bcl-2 down-regulation was par-
tially reversed, and the selenite-induced activation of PARP and
caspase-9 was suppressed (Fig. 2E). The Annexin V/PI double stain-
ing results demonstrate that the selenite-induced apoptosis was
suppressed after the overexpression of CREB (Fig. 2F, Supplementary
Fig. 2F).
Finally, to fully determine the function of CREB in this system,
we treated CRC cells with CREB binding protein (CBP)–CREB inter-
action inhibitor, and then exposed these cells to selenite for 24 h.
The western blot results indicated that the inhibition of CREB tran-
scriptional activity further resulted in enhanced selenite-induced
inhibition of Bcl-2 expression and increased PARP and caspase-9
cleavage (Fig. 2G). The apoptotic rate of these cells, as detected with
the Annexin V/PI double staining assay, demonstrated that CREB in-
hibition enhanced the amount of apoptosis of selenite-treated CRC
cells (Fig. 2H, Supplementary Fig. 2H).
Selenite-induced inhibition of PKD1 activation is required for CREB
signalling pathway suppression
A large body of evidence has indicated that activated PKD1 phos-
phorylates CREB at Ser133, which enhances its transcriptional activity
[21,26,27]. To determine whether selenite regulates PKD1 activa-
tion and whether this effect could exert any impact on CREB
signalling in CRC cells, we performed a series of experiments. First,
we found that the knockdown of PKD1 by siRNA transfection, the
over-expression of a dominant negative PKD1 (PKD1 kinase dead
(KD)) or the administration of CID 755673 (a PKD1 inhibitor) in-
hibited CREB phosphorylation, which decreased p-CREB-dependent
Bcl-2 expression and PARP and caspase-9 cleavage (Fig. 3A, C, E).
The analysis of the apoptotic rate with the Annexin V/PI double stain-
ing assay demonstrated that PKD1 inhibition increased the apoptosis
rate of selenite-treated CRC cells (Fig. 3B, D, F and Supplementary
Fig. 3B, D, F).
In another set of experiments, we over-expressedwild-type PKD1
(PKD1WT) or treated cells with the PKD1 activator PMA. Thewestern
blot results demonstrated that both PKD1WT over-expression and
PMA treatment sharply increased the p-CREB and Bcl-2 levels even
in the presence of selenite treatment, compared with selenite treat-
ment alone (Fig. 3C, G). The analysis of the apoptotic rate with the
Annexin V/PI double staining assay demonstrated that PKD1 acti-
vation or over-expression could partially rescue selenite-induced
apoptosis (Fig. 3D, H and Supplementary Fig. 3D, H).
Next, to verify whether CREB is a PKD1 substrate, we per-
formed a co-immunoprecipitation experiment. As shown in Fig. 3I,
selenite treatment greatly decreased the association between p-PKD1
and p-CREB in CRC cells. This result suggested that the reduction
in CREB phosphorylation may be partly attributable to the selenite-
induced disruption of the association between PKD1 and CREB.
Furthermore, our immunoﬂuorescence results (Fig. 3J) support
the conclusion earlier that selenite reduced CREB phosphoryla-
tion in the nucleus. Taken together, these results indicate that selenite
inhibited CREB/Bcl-2 survival signalling via PKD1 activity in CRC
cells.
p38 MAPK inhibits the PKD1/CREB/Bcl-2 survival signalling pathway
in selenite-treated CRC cells
We discovered that PKD1 plays an important role in regulating
the CREB/Bcl-2 axis. We then determined which upstream signal
causes PKDI inhibition. After screening several proteins, we found
that p38MAPK inhibits PKD1 activation in selenite-treated CRC cells.
First, we validated the interaction between p38 MAPK and PKD1
by co-immunoprecipitation and found that this binding was
enhanced after selenite exposure (Fig. 4A). In addition, the
co-localisation of p38 MAPK and PKD1 was observed by immuno-
ﬂuorescence staining, which conﬁrms the immunoprecipitation
results (Fig. 4B).
To elucidate the role of p38 MAPK in the selenite-induced apop-
tosis in CRC cells, we pretreated CRC cells with siRNA targeting p38
MAPK or the p38MAPK inhibitor SB203580 before exposing the cells
to selenite for 24 h. Our western blot results showed that either the
knockdown or inhibition of p38 MAPK reversed the selenite-
mediated inhibition of the PKD1/CREB/Bcl-2 signalling pathway and
resulted in decreased cleavage of PARP and caspase-9 (Fig. 4C, E).
The analysis of the apoptotic rate using the Annexin V/PI double
staining assay demonstrated that the knockdown or inhibition of
p38 MAPK reversed the selenite-induced apoptosis in CRC cells
(Fig. 4D, F and Supplementary Fig. 4D, F).
Finally, to fully demonstrate the function of p38 MAPK in this
system, we over-expressed p38MAPKWT or p38MAPK domain neg-
ative (p38 MAPK DN) in CRC cells. We observed that p38 MAPKWT
overexpression sharply enhanced the selenite-induced PKD1/CREB/
Bcl-2 inhibition compared with selenite treatment alone.
Simultaneously, p38MAPKDN over-expression reversed the selenite-
induced PKD1/CREB/Bcl-2 inhibition in CRC cells (Fig. 4G). We found
that the selenite-induced apoptosis was suppressed upon p38MAPK
DN over-expression, whereas the selenite-induced apoptosis was
further enhanced after p38 MAPKWT over-expression (Fig. 4H and
Supplementary Fig. 4H). All of these data strongly suggest that p38
MAPK inhibits the PKD1/CREB/Bcl-2 survival signalling pathway in
selenite-treated CRC cells.
Fig. 4. p38 MAPK induces apoptosis by inhibiting the PKD1/CREB/Bcl-2 survival signalling pathway in selenite-treated CRC cells. (A) p38 MAPK interacted with PKD1. The
cells were exposed to 10 μM selenite for 24 h, and co-immunoprecipitation was used to detect the interactions between p38 MAPK and PKD1. (B) The co-localisation of p38
MAPK and PKD1. The cells were treated with 10 μM selenite for 24 h. p38 MAPK and PKD1 were indirectly labelled with primary antibodies. The images were generated
with a confocal microscope. Bar: 10 μm. (C and E) Inhibition of p38 MAPK induced further inhibition of the PKD1/CREB/Bcl-2 axis inhibition. The cells were transfected
with siRNA targeting p38 MAPK or pretreated with 10 μM SB203580 for 2 h. After the cells were treated with 10 μM selenite for 24 h, the p38 MAPK, PKD1, CREB, Bcl-2
and apoptosis marker levels were detected by western blot and quantiﬁed by pixel densitometry. (D and F) Inhibition of p38 MAPK reverses the selenite-induced apoptosis
in CRC cells. The cells were treated as described in (C and E), and the apoptotic cells were measured by ﬂow cytometry. The data are represented as the means ± SD (n = 3).
*P < 0.05. (G) p38 MAPK inhibits the PKD1/CREB/Bcl-2 signalling pathway. The cells were transfected with p38 MAPK WT or DN plasmids. After the cells were treated with
10 μM selenite for 24 h, the p38 MAPK, PKD1, CREB, Bcl-2 and apoptosis marker levels were detected by western blot and quantiﬁed by pixel densitometry. (H) p38 MAPK
enhances the selenite-induced apoptosis in CRC cells. The cells were treated as described in (G), and the apoptotic cells were measured by ﬂow cytometry. The data are
represented as the means ± S.D (n = 3). *P < 0.05.
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The p38 MAPK/PKD1/CREB signalling pathway is regulated by
selenite in vivo
After exploring the important role of the p38 MAPK/PKD1/
CREB axis following selenite treatment in vitro, further experiments
were conducted to investigate the effects of selenite in vivo. Four-
week-old female nude mice were injected with HCT116 and SW480
cells. Once tumourswere detectable, themicewere randomly divided
into three groups and administered PBS or selenite (2 mg/kg/day
or 1 mg/kg/day) through an intraperitoneal injection every 2 days.
After treatment with selenite for 3 weeks, mice were killed for anal-
ysis. We discovered that selenite treatment markedly attenuated
tumour growth compared with the control group without any
adverse effects on body weight and activity (Fig. 5A). Tissues from
the group treated with 2 mg/kg/day sodium selenite were pro-
cessed for western blot and immunohistochemistry experiments.
To verify the in vitro results, we ﬁrst performed an analysis of
the tissues from both control and selenite-treated samples by
western blot. The results revealed that selenite activated p38 MAPK
and inhibited the PKD1/CREB/Bcl-2 survival signalling pathway,
thereby inhibiting tumour growth (Fig. 5B and Supplementary Fig.
5B). Additionally, through a series of immunohistochemistry ex-
periments, we examined the localisation patterns of critical
molecules in this signalling pathway. We observed that p38 MAPK
phosphorylation was increased and that PKD1/CREB phosphoryla-
tion and Bcl-2 expression were decreased in tissues from the group
treated with a supranutritional dose of sodium selenite. In con-
trast, p38, PKD1 and CREB did not show any obvious changes
(Fig. 5C).
Discussion
This study presents evidence that the p38 MAPK/PKD1/CREB/
Bcl-2 signalling pathway is closely associated with selenite-
induced apoptosis in CRC cells and xenograft tumours. A model
depicting our ﬁndings is presented in Fig. 6. Brieﬂy, selenite acti-
vates p38 MAPK, which further inhibits PKD1. As a result, CREB, the
downstream mediator of PKD1, becomes inactivated and then
inhibits the expression of anti-apoptotic Bcl-2. This discovery
elucidates a mechanism through which selenite imparts anti-
tumour activity.
Selenite induces apoptosis by regulating the ATF/CREB family of
transcription factors [28]. CREB, a member of the ATF/CREB family,
plays an important role in cancer cell survival, and the phosphory-
lation of residue Ser133 is involved in its transcriptional activity
[19,29]. Our data demonstrated that CREB phosphorylation was sup-
pressed in selenite-treated CRC cells, which indicated that selenite
may induce apoptosis by inhibiting the transcriptional activity of
CREB. By performing a ChIP assay, we found that p-CREB inter-
acted with the Bcl-2 promoter in CRC cells and that selenite
treatment disrupted this binding. Bcl-2 is widely known for its anti-
apoptotic function in various cancer cell lines, and the inhibition
of Bcl-2 expression is an effective method for cancer therapy [30].
Selenite induces apoptosis by inhibiting the expression of Bcl-2, al-
though the mechanism is unclear [6,25,31]. Notably, our over-
expression and knockdown results veriﬁed that CREB is involved
in selenite-induced apoptosis through its regulation of Bcl-2 ex-
pression. CREB-binding protein (CBP) is an important co-activator
of CREB and plays a role in the transcription of CREB-dependent
genes [32,33]. To conﬁrm themechanism through which CREB regu-
lates Bcl-2 expression, we pretreated CRC cells with CBP–CREB
interaction inhibitor and then treated the cells with selenite. This
experiment indicated that Bcl-2 expression required the transcrip-
tional activity of CREB. Overall, selenite decreases the Bcl-2
expression by inhibiting the transcriptional activity of CREB in CRC
cells. It has been reported that CREB regulates Bcl-2 expression in
other cancer cells, such as non-small cell lung cancer (NSCLC) cell
lines, MCF7 breast cancer cells and HeLa cell lines, which is con-
sistent with our conclusion [8,13,34].
An increasing body of evidence suggests a role for PKD1 in pro-
liferation and survival by activating CREB in various cancer cell lines
[21,26]. However, whether PKD1 is involved in the regulation of CREB
in selenite-treated CRC cells was unknown. In this study, we found
that PKD1 reversed the selenite-induced reduction of p-CREB. More-
over, studies with CRC cells treated with selenite combined with
CID 755673 (PKD1 inhibitor) or PMA (PKD1 activator) indicated that
the PKD1-mediated phosphorylation of p-CREB required the kinase
activity of PKD1. However, a previous report indicated that the H2O2-
induced inhibition of CREB via a PKD1-dependent mechanism did
not require Ser133 phosphorylation [35]. To determinewhether PKD1
phosphorylates CREB directly or indirectly in CRC cells, we per-
formed co-immunoprecipitation and immunoﬂuorescence
experiments. The results from these experiments showed that PKD1
directly phosphorylated CREB and that the selenite-induced
de-phosphorylation of PKD1 led to the inhibition of CREB phos-
phorylation in CRC cells. Moreover, studies conducted by Nguyen
et al. [36] and Huang et al. [37] concluded that CREB can promote
cancer cell survival via PI3K/AKT-dependent activation. Our previ-
ous study also provided evidence that selenite can induce CRC cells
apoptosis by inhibiting the PI3K/AKT survival pathway [7]. Thus,
further studies need to be performed to explore the crosstalk
between PKD1/CREB and other survival pathways, which are a main
focus of our future research.
It has been reported that p38 MAPK acts as a tumour suppres-
sor in various cancer cells, and our previous work indicated that p38
MAPK was involved in selenite-induced apoptosis [28]. Activated
p38MAPK can induce apoptosis by regulating several protein kinases,
such as MAPK-activated kinase 2 (MK2) and MSK1 [38]. However,
whether p38 MAPK is involved in the regulation of PKD1 signal-
ling in selenite-treated CRC cells remains unknown. Here, we found
that p38 MAPK binds to PKD1 and that their interaction was en-
hanced in selenite-treated CRC cells. Additional experiments showed
that the up-regulation of p-p38 MAPK induced apoptosis by inhib-
iting the PKD1 survival pathway. The study conducted by Ricci [39]
demonstrated that p38 MAPK inhibits PKD1, which strongly sup-
ports our conclusion.
Previous work in our lab demonstrated that a supranutritional
dose of sodium selenite (2 mg/kg/day) had anticancer effects on
SW480 cell lines in nude mice [40]. To demonstrate that this
supranutritional dose of sodium selenite is appropritate for cancer
therapy, we treated mice with two different doses: 2 mg/kg/day or
1 mg/kg/day. The average tumour volume of the 2 mg/kg/day-
dose sodium selenite-treatment group was signiﬁcantly reduced
compared with the control and the 1-mg/kg/day-dose sodium
selenite-treated group. Moreover, the TUNEL assay results re-
ported by Luo [41] and Wu [20] support our conclusion that a
supranutritional dose of sodium selenite induces apoptosis in xe-
nograft tumours. Furthermore, our analyses of the apoptosis-
related signalling pathways in tumour tissues were in agreement
with our in vitro studies.
We discovered that selenite treatment did not have obvious effects
on body weight and activity of nude mice, which is consistent with
our previous work [40]. Normal mice were treated with selenite
(2 mg/kg/day) or PBS, and then liver tissues from both control and
selenite-treated mice were analysed by hematoxylin–eosin (HE)
staining. Comparing with the liver tissues in control group, there
were nomarked pathological changes in the liver tissues of selenite-
treated group (unpublished data). To verify the potential toxicity
of selenite on normal cells, we treated monocytes with selenite
(10 μM) and found selenite had no obvious toxicity for monocytes
(Supplementary Table S1). Our results also are supported by thework
of Nilsonne et al. [42] and Husbeck et al. [43], which showed
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Fig. 5. The p38 MAPK/PKD1/CREB axis is altered by selenite in vivo. (A) Selenite treatment of tumour-bearing mice markedly attenuated tumour growth. (B) Western blot analysis of proteins extracted from tumour tissues
using antibodies against the molecules indicated and quantiﬁed by pixel densitometry. (C) Selenite-mediated regulation of the p38 MAPK/PKD1/CREB signalling pathway in vivo. Tumour tissues from a colon xenograft animal
model were analysed by immunohistochemistry with antibodies speciﬁc for p38 MAPK, p38, p-PKD1, PKD1, p-CREB, CREB and Bcl-2. Bar: 50 μm.
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selenite selectively killed the cancer cells while has little effect on
normal cells. Olm’s [44] work showed cancer-speciﬁc cytotoxicity
of selenite may be due to speciﬁc high uptake and accumulation
in malignant cells. To be concluded, selenite could induce cancer
cell apoptosis with less toxicity in vivo and had potential clinical
applications.
Supplemental Table S1. Selenite had no obvious toxicity on
monocytes. Monocytes were isolated from umbilical cord blood of
a normal person. After treatment of selenite for various lengths of
time, live cells were counted. Result showed there is no signiﬁ-
cant difference between control group and selenite treated group
(p > 0.05).
In summary, our study demonstrated that selenite induces apop-
tosis in CRC cells through the p38 MAPK-regulated PKD1/CREB/
Bcl-2 signalling pathway. These ﬁndings provide a theoretical basis
for the use of sodium selenite in clinical applications as a treat-
ment for malignant tumours.
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